Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale.

MLA

Dürig, Jan, et al. “Subcutaneous Rituximab in Patients with Diffuse Large B Cell Lymphoma and Follicular Lymphoma: Final Results of the Non‐interventional Study MabSCale.” Cancer Medicine, vol. 12, no. 3, Feb. 2023, pp. 2739–51. EBSCOhost, https://doi.org/10.1002/cam4.5160.

APA

Dürig, J., Uhlig, J., Gerhardt, A., Ritter, M., Hapke, G., Heßling, J., Staib, P., Wolff, F., Krumm, K., & von Weikersthal, L. F. (2023). Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale. Cancer Medicine, 12(3), 2739–2751. https://doi.org/10.1002/cam4.5160

Chicago

Dürig, Jan, Jens Uhlig, Anke Gerhardt, Markus Ritter, Gunnar Hapke, Jörg Heßling, Peter Staib, Frieder Wolff, Katja Krumm, and Ludwig Fischer von Weikersthal. 2023. “Subcutaneous Rituximab in Patients with Diffuse Large B Cell Lymphoma and Follicular Lymphoma: Final Results of the Non‐interventional Study MabSCale.” Cancer Medicine 12 (3): 2739–51. doi:10.1002/cam4.5160.